Celsion Co. (CLSN) Raised to "Buy" at Zacks Investment Research
The firm currently has a $1.50 price objective on the stock. Zacks Investment Research 's price objective would indicate a potential upside of 16.28% from the company's previous close.
from Biotech News
0 Comments